Language
English
Publication Date
1-8-2025
Journal
Biomolecules
DOI
10.3390/biom15010079
PMID
39858473
PMCID
PMC11764227
PubMedCentral® Posted Date
1-8-2025
PubMedCentral® Full Text Version
Post-print
Abstract
We previously reported that PRDM16 mediated the improvement in body composition in testosterone (T)-treated hypogonadal men by shifting adipogenesis to myogenesis. Previous preclinical studies suggest that Prdm16 regulates Runx2, an important osteoblastic transcription factor, expression and activity. However, the changes in PRDM16, and other genes/proteins involved in osteoblastogenesis with T therapy in hypogonadal men are unexplored. We investigated the role of PRDM16 in RUNX2 activation by measuring changes in gene expression in peripheral blood monocytes (PBMCs) and proteins in the serum of hypogonadal men after T therapy for 6 months. Likewise, we evaluated changes in the WNT10b—β-CATENIN signaling pathway by gene expression and protein analyses. We found significant increases in PRDM16 and RUNX2 expression in PBMCs together with significant increases in serum proteins at 6 months when compared to baseline. There were also increases in gene and protein expressions of WNT10b, and β-CATENIN at 6 months. Furthermore, we found a significant positive correlation between % changes in PRDM16 and WNT10b. Our results suggest that T therapy activates PRDM16, leading to enhanced signaling in the canonical WNT10b—β-CATENIN-RUNX2 pathway, the pathway involved in osteoblastogenesis. The above findings may account for the improvement in bone density and quality in hypogonadal men treated with T.
Keywords
Humans, Male, Core Binding Factor Alpha 1 Subunit, Testosterone, Transcription Factors, beta Catenin, Wnt Proteins, Hypogonadism, DNA-Binding Proteins, Middle Aged, Osteoblasts, Adult, Osteogenesis, Signal Transduction, Proto-Oncogene Proteins, PRDM16, RUNX2, osteoblastogenesis, BMD
Published Open-Access
yes
Recommended Citation
Bathina, Siresha; Prado, Mia; Fuenmayor Lopez, Virginia; et al., "PRDM16 Enhances Osteoblastogenic RUNX2 via Canonical WNT10b/β-CATENIN Pathway in Testosterone-Treated Hypogonadal Men" (2025). Faculty and Staff Publications. 4352.
https://digitalcommons.library.tmc.edu/baylor_docs/4352